SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

A Korean cohort study found fewer kidney cancer cases among patients with type 2 diabetes who initiated sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors.

By
Andrea Surnit
June 9, 2026
5 min

MDSpire News

1

SGLT2 inhibitors are associated with a lower incidence of kidney cancer compared to DPP-4 inhibitors in patients with type 2 diabetes.
2

The study involved 57,103 users of SGLT2 inhibitors and 57,103 users of DPP-4 inhibitors, with a follow-up of approximately 3.5 years.
3

SGLT2 inhibitor users had a 40% lower hazard of kidney cancer, with an incidence rate of 18.9 cases per 100,000 person-years.
4

The findings suggest potential mechanisms for reduced kidney cancer risk, but these were not directly tested in the study.
5

Limitations include observational design, short follow-up, and lack of individual agent data, affecting generalizability and potential confounding.

SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

1

2

3

4

5

Original Source(s)

SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

Related Content

Neuroretinal damage associated with pituitary macroadenoma: endocrine and radiological predictors and correlation with optical coherence tomography-derived biomarkers

Case Report: Preoperative embolization for a large intracranial pheochromocytoma metastasis: a novel approach to minimize intraoperative risk

Modified-release hydrocortisone (Efmody®) in children with congenital adrenal hyperplasia: a retrospective registry study